Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1997 1
2010 1
2011 1
2012 1
2014 1
2015 1
2016 2
2017 4
2018 1
2019 2
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Oliva EN, et al. Among authors: impera s. J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9. J Clin Oncol. 2023. PMID: 37294914 Free PMC article. Clinical Trial.
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).
Guglielmelli P, Palandri F, Selleri C, Cilloni D, Mendicino F, Mazza P, Pastore D, Palumbo GA, Santoro M, Pavone V, Impera S, Morelli M, Coco P, Valsecchi D, Passamonti F, Breccia M; ROMEI study group. Guglielmelli P, et al. Among authors: impera s. Leuk Lymphoma. 2022 Jan;63(1):189-198. doi: 10.1080/10428194.2021.1969388. Epub 2021 Sep 15. Leuk Lymphoma. 2022. PMID: 34521299
CD34 expression in adult acute lymphoblastic leukemia.
Cacciola E, Guglielmo P, Cacciola E, Stagno F, Cacciola RR, Impera S. Cacciola E, et al. Among authors: impera s. Leuk Lymphoma. 1995;18 Suppl 1:31-6. doi: 10.3109/10428199509075300. Leuk Lymphoma. 1995. PMID: 7496352
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
Palandri F, Auteri G, Abruzzese E, Caocci G, Bonifacio M, Mendicino F, Latagliata R, Iurlo A, Branzanti F, Garibaldi B, Trawinska MM, Cattaneo D, Krampera M, Mulas O, Martino EA, Cavo M, Vianelli N, Impera S, Efficace F, Heidel F, Breccia M, Elli EM, Palumbo GA. Palandri F, et al. Among authors: impera s. Ann Hematol. 2024 Jun;103(6):1931-1940. doi: 10.1007/s00277-024-05704-0. Epub 2024 Mar 13. Ann Hematol. 2024. PMID: 38478023 Free PMC article. Clinical Trial.
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.
Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P. Pennisi MS, et al. Among authors: impera s. Front Oncol. 2019 Aug 13;9:764. doi: 10.3389/fonc.2019.00764. eCollection 2019. Front Oncol. 2019. PMID: 31456947 Free PMC article.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F. Stella S, et al. Among authors: impera s. Int J Mol Sci. 2019 May 6;20(9):2226. doi: 10.3390/ijms20092226. Int J Mol Sci. 2019. PMID: 31064152 Free PMC article.
JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.
Barosi G, Klersy C, Villani L, Bonetti E, Catarsi P, Poletto V, Campanelli R, Impera S, Latagliata R, Viarengo G, Carolei A, Massa M, Musso M, Crescimanno A, Gale RP, Rosti V. Barosi G, et al. Among authors: impera s. Leukemia. 2016 Aug;30(8):1772-5. doi: 10.1038/leu.2016.45. Epub 2016 Feb 29. Leukemia. 2016. PMID: 26975727 Clinical Trial. No abstract available.
Differences among young adults, adults and elderly chronic myeloid leukemia patients.
Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Ann Oncol. 2015 Jan;26(1):185-192. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361995 Free article. Clinical Trial.
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M. Castagnetti F, et al. Among authors: impera s. Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18. Am J Hematol. 2017. PMID: 27770583 Free article.
18 results